Menu
X
image

Clinical Trials

If interested in volunteering to participate in a clinical research trial, or if you have concerns about the conduct of clinical research, please contact the Clinical Research office at (225) 215-1353, or by email at clinicalresearch@marybird.com.

ABOUT CLINICAL TRIALS

Research is key to the future of cancer care. Clinical trials enhance standard cancer treatments, resulting in improved patient outcomes and survival rates.

Every patient at Mary Bird Perkins-Our Lady of the Lake Cancer Center is evaluated for participation in a clinical trial. Those who meet the criteria to participate in clinical research receive a standard of care treatment, but with the added benefit of a trial that may enhance their outcomes.

Through a National Cancer Institute Community Oncology Research Program (NCORP) grant presented to LSU Health Sciences Centers in New Orleans and Shreveport, in collaboration with the Cancer Center, more advanced clinical trials are offered to patients statewide. This effort reaches about 80 percent of Louisiana residents, particularly minority populations, providing patients access to high-quality research studies closer to home.

The Cancer Center sponsors clinical trials to seek the safest and most effective treatments for each cancer type. Patients considering participating in one of our clinical trials will receive a thorough explanation from their doctor with information needed to make an informed decision. Physicians offer many clinical trials at any given time, including brain, breast, colorectal, head and neck, kidney, lung, melanoma, pancreas and prostate studies.

For more information on clinical research trials, please fill out the form below and a team member will contact you.

WHAT IS A CLINICAL TRIAL?
Clinical trials are research studies that involve human beings in order to test new ways to prevent, detect, diagnose or treat diseases. A drug must be part of a clinical trial before the FDA will approve it to be put on the market.

WHAT IS THE PURPOSE OF ONCOLOGY CLINICAL TRIALS?
Oncology clinical trials are conducted in order to test new drugs or a new combination of drug treatments, new surgery and radiation therapies and new medical devices.

HOW DO I JOIN A TRIAL?
There are three ways you can sign up for a clinical trial:

  1. Physician Referral: Ask your doctor about participating in one of our trials.
  2. Phone: Call our clinical research department
  3. Email: Contact our clinical research department at clinicalresearch@marybird.com.
BLADDER/UROTHELIAL

Information on open clinical trials for bladder and urothelial cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Purpose:  This randomized phase III trial studies how well Pembrolizumab works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes. Monoclonal antibodies, such as Pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, and Jack Saux; and Naveed Khan.

Offered in:  Baton Rouge, Covington, Houma

Title: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Purpose: This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without Nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as Nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving Nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether Nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.

Physicians: Drs. Vince CataldoJoseph Shows,  Siva Yadlapati and Lauren Zatarain; James Carinder, and Jack Saux; and Naveed Khan.

Offered in:  Baton Rouge, Covington, Houma

BREAST

Information on open clinical trials for breast cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: A Randomized Phase III Trial Comparing Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Purpose: This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

Physicians: Drs. Mindy Bowie, and Cecilia Cuntz.

Offered in: Baton Rouge

Title: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Purpose: This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Physicians: Drs. Katherine Castle, Robert Fields, Maurice KingJingya Wang, and Charles Wood; Andrew Elson; Jeffery Long

Offered in: Baton Rouge, Covington, Houma

Title: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Purpose: This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.

Physicians: Dr. James Ruiz

Offered in: Baton Rouge (Woman’s Hospital)

Title: A Randomized, Open Label, Phase 3 Study of Ademaciclib Combined with Standard Adjuvant Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Purpose: The purpose of this study is to evaluate the safety and efficacy of the study drug Abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Physicians: Drs. Bryan Bienvenu, Vince CataldoDavid Hanson, Kellie Schmeeckle, Joseph Shows, Siva Yadlapati and Derrick Spell

Offered in: Baton Rouge

Title: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

Purpose: The objectives of this prospective NIS of Palbociclib in ABC treatment are to describe and analyze Palbociclib prescribing and treatment patterns in routine clinical practice, metastatic breast cancer (MBC) treatment sequencing prior to, during, and after Palbociclib, patient quality of life, geriatric specific assessment; and to explore biomarkers underlying resistance or response mechanisms to Palbociclib treatment.

Physicians: Drs. Bryan BienvenuDavid Hanson, Kellie Schmeeckle, and Derrick Spell

Offered in: Baton Rouge

Title: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Purpose: This study is to compare the safety and effects of Donepezil (Aricept) or if it decreases memory loss after receiving chemotherapy for breast cancer.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph ShowsDerrick SpellSiva Yadlapati and Lauren Zatarain; James Carinder, and Jack Saux; and Naveed Khan.

Offered in: Baton Rouge, Covington, Houma

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Purpose: This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

Physicians: Drs. Bryan Bienvenu, Vince CataldoDavid Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati Lauren Zatarain, Naveed Khan,  James Carinder and Jack Saux.

Offered in: Baton Rouge, Covington, Houma

Title:  A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Purpose:  This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

Physicians: Drs. Katherine Castle, Robert Fields, Maurice King, Jingya Wang and Charles Wood; Andrew Elson;  Jeffrey Long.

Offered in:  Baton Rouge, Covington, Gonzales, Hammond and Houma

Title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study)

Purpose: This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, Robert Fields, David Hanson, Maurice KingKellie Schmeeckle, Joseph Shows, Derrick Spell, Jingya Wang, Charles Wood, Siva Yadlapati Lauren Zatarain;  James Carinder, Andrew Elson, Jack Saux, Naveed Khan, and Jeffrey Long.

Offered in: Baton Rouge, Covington, Houma

Title:  A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Purpose: This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati Lauren Zatarain,  James Carinder, and Jack Saux, and Naveed Khan.

Offered in: Baton Rouge, Covington, Houma

Title:  A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Purpose: This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati, Lauren Zatarain;  James Carinder, Jack Saux and Naveed Khan.

Offered in: Baton Rouge, Covington, Houma

Title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor- Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neodajuvant Chemotherapy

Purpose: The primary objective is to compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >1 cm residual invasive breast cancer and/or positive lymph nodes (>ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset.

Physicians:  Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Derrick Spell, James Carinder, Jack SauxNaveed KhanVince Cataldo, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

Title: A Randomized, Double-Blinded, Phase III Trial of Paclitaxel/ Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positice Metastatic Breast Cancer

Purpose: This randomized phase III trial studies how well Paclitaxel, Trastuzumab, and Pertuzumab with or without Atezolizumab works in treating patients with breast cancer that has spread to other parts of the body.

Physicians:  Drs. Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVieKellie Schmeeckle, Derrick Spell, James Carinder, Jack SauxNaveed Khan, Genevieve MaronageVince Cataldo, Sobia OzairJoseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

CARCINOID

There are currently no active carcinoid clinical trials. Please check back as we are continuously opening new studies.

If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

COLORECTAL

Information on open clinical trials for colorectal cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent

Purpose: This research trial studies the financial burden in patients with stage I-III colon or rectal cancer who are undergoing treatment.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, Robert Fields, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren ZatarainJames Carinder and Jack Saux; Naveed Khan, and Genevieve Maronage.

Offered in: Baton Rouge, Covington, Houma

Title: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)

Purpose: This randomized phase III trial studies combination chemotherapy and Atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as Oxaliplatin, Leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as Atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with Atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

Physicians: Drs. Bryan BienvenuVince CataldoDavid HansonKellie SchmeeckleJoseph ShowsDerrick SpellSiva Yadlapati, and Lauren ZatarainJames Carinder, and Jack Saux and Naveed Khan.

Offered in: Baton Rouge, Covington, Houma

Title: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Purpose: This randomized phase II trial studies how well Veliparib or Pembrolizumab work with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced).

Physicians: Drs. Katherine Castle, Jingya Wang, Charles Wood, Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, Andrew Elson, James Carinder, Jack Saux, Jeffrey Long, Robert Gamble, Naveed Khan, Genevieve Maronge, Vince Cataldo, Sobia Ozair, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

ESOPHAGEAL

There are currently no active esophageal clinical trials. Please check back as we are continuously opening new studies.

If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

GASTRIC

Information on open clinical trials for gastric cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Purpose: This phase III trial studies how well Gemcitabine Hydrochloride and Cisplatin given with or without Nab-Paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body.

Physicians: Drs. Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, Vince Cataldo, Sobia Ozair, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge

GYNECOLOGY

Information on open clinical trials for GYN cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemo radiation in Intermediate Risk Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Purpose: This randomized phase III trial studies radiation therapy with chemotherapy to see how well it works compared to radiation therapy alone in treating patients with stage I or stage II cervical cancer who previously underwent surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation therapy together with chemotherapy is more effective than radiation therapy alone in treating patients with cervical cancer.

Physicians: Dr. Patricia Braly

Offered in: Baton Rouge (Breast & GYN Cancer Pavilion), Covington

Title: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Purpose: This trial studies how well Cediranib maleate and Olaparib work when given together or separately. Further comparing them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

Physicians: Drs. David S. Hanson, Jeanette Kovtun, Sobia Ozair, Kellie D. Schmeeckle, Derrick W. Spell, Lauren Zatarain; Patricia Braly

Offered in: Baton Rouge (Breast & GYN Cancer Pavilion), Covington

HEAD & NECK

Information on open clinical trials for head and neck cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: A Randomized Phase III Study of Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy versus Chemoradiation alone in Subjects with Locally Advanced Head and Neck Squamous Cell Carcinoma

Purpose: The purpose of this study is to determine the efficacy and safety of Pembrolizumab given concomitantly with Chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that Pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review (BICR).

Physicians: Drs. Bryan Bienvenu

Offered in: Baton Rouge

LIVER

There are currently no active liver clinical trials. Please check back as we are continuously opening new studies.

If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

LUNG

Information on open clinical trials for lung cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients who Smoke Cigarettes

Purpose: This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares Varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence from nicotine) and behavioral interventions (consisting of a brief clinician-delivered intervention and tobacco quitline [tobacco cessation service available through a toll-free telephone number] follow-up) with placebo (a pill with no active medication) along with similar behavioral interventions. It is not yet known whether management of a tobacco treatment intervention is more effective in reducing surgical complications than placebo.

Physicians: Drs. Jingya Wang, Charles Wood, Siva Yadlapati and Lauren Zatarain; James Carinder, Andrew Elson, and Jack Saux, Naveed Khan, and Jeffrey Long.

Offered in: Baton Rouge, Covington, and Houma.

Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Purpose: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient’s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick SpellSiva Yadlapati and Lauren Zatarain; James Carinder, and Jack Saux, and Naveed Khan.

Offered in: Baton Rouge, Covington, and Houma.

Title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Purpose: This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Physicians: Drs. Bryan Bienvenu, Vince CataldoDavid Hanson, Kellie Schmeeckle, Joseph Shows, Derrick SpellSiva Yadlapati and Lauren Zatarain; James Carinder, and Jack Saux, and Naveed Khan.

Offered in: Baton Rouge, Covington, and Houma.

Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Purpose: This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, and Jack Saux, and Naveed Khan.

Offered in: Baton Rouge, Covington, and Houma.

Title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Purpose: This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain James Carinder, and Jack Saux and Naveed Khan.

Offered in: Baton Rouge, Covington, and Houma.

Title: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Purpose: This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer.

Physicians: Drs. Katherine Castle, Jingya Wang, Charles Wood, Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, Vince Cataldo, Sobia Ozair, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge

Title: A Master Protocol to Evaluate Biomarker – Driven and Immunotherapies in Previously – Treated Non – Small Cell Lung Cancer (Lung – MAP Screening Study)

Purpose: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP).

Physicians: Drs. Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, James Carinder, Jack Saux, Naveed Khan, Genevieve Maronge, Vince Cataldo, Sobia Ozair, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

Title: A Randomized Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited SCLC also Receiving Cisplatin and Etoposide

Purpose: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as Etoposide, Carboplatin and Cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Physicians: Drs. Katherine Castle, Jingya Wang, Charles Wood, Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, Andrew Elson, James Carinder, Jack Saux, Jeffrey Long, Robert Gamble, Naveed Khan, Genevieve Maronge, Vince Cataldo, Sobia Ozair, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

LYMPHOMA

Information on open clinical trials for lymphoma cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/ Refractory Hodgkin Lymphoma

Purpose: This phase I/II trial studies the side effects and best dose of Ipilimumab and Nivolumab when given together with Brentuximab Vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment.

Physicians: Drs. Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, James Carinder, Jack Saux, Naveed Khan, Genevieve Maronge, Vince Cataldo, Sobia Ozair, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

MULTI SITE/MULTI DISEASE

Information on open clinical trials for multiple sites/diesease are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: Olanzanpine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Recieveing Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double-Blind, Placebo-Controlled Trial

Purpose: This randomized phase III trial studies how well Olanzapine with or without Fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting.

Physicians: Physicians: Drs. Bryan Bienvenu, Vince Cataldo, Robert Fields, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren ZatarainJames Carinder and Jack Saux, Naveed Khan, and Genevieve Maronage.

Offered in: Baton Rouge, Covington, Houma

Title: Use of Clinical Trial Screenining Selection Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program

Purpose: The objectives of this study are:

1) Implement a screening tool in NCORP to collect broader demographic and clinical data to generate hypothesis and research questions in the following areas of research: cancer screening, cancer prevention, symptom science, cancer care disparities, comparative effectiveness and cancer care delivery research.

2) Collect expanded demographic and clinical data (e.g., SES, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled and for patients that participate in NCI trials, to understand how these variables may impact outcomes.

3) Enhance an understanding of site- specific and trial-specific accrual barriers that will inform the development of effective strategies to improve accrual, particularly for minority and underserved populations.

4) Provide data for internal and external evaluation of NCORP’s first RFA cycle and reissuance.

Physicians: Drs.  Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick SpellSiva Yadlapati Lauren Zatarain; James CarinderJack Saux, Naveed KhanRobert Fields, Katherine Castle, Maurice KingCharles Wood, Jingya Wang, Jeffery Long, Andrew Elson, and R Scott Bermudez

Offered in: Baton Rouge, Covington, and Houma.

MULTIPLE MYELOMA

There are currently no active multiple myeloma clinical trials. Please check back as we are continuously opening new studies.

If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

NEURO

Information on open clinical trials for neuro cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)

Purpose: This randomized phase III trial studies Cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with Everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery.

Physicians: Drs. Bryan Bienvenu, David Hanson, Jeanette Kovtun, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, James Carinder, Jack Saux, Naveed Khan, Genevieve Maronge, Vince Cataldo, Sobia Ozair, Joseph Shows, Siva Yadlapati, and Lauren Zatarain

Offered in: Baton Rouge, Covington, Houma

OBSERVATIONAL TRIALS

Information on open observational clinical trials are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

Purpose: The purpose of this study is to use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression. In addition, information is being collected to help better understand patterns for the quality of life in patients newly diagnosed with Lower-Risk, Higher-Risk, or unknown risk MDS or AML. The final reason is to use the results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.

Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle and Derrick Spell

Offered in: Baton Rouge

OVARIAN

There are currently no active ovarian clinical trials. Please check back as we are continuously opening new studies.

If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

PANCREATIC

Information on open clinical trials for pancreatic cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: A Phase III Study of BBI-608 plus nab-paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

Purpose: This is a randomized, open-label, multi-center; phase 3 study of Napabucasin plus weekly Nab-paclitaxel with Gemcitabine versus weekly Nab-paclitaxel with Gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Physicians: Drs. Vince Cataldo, Joseph ShowsSiva Yadlapati and Lauren Zatarain

Offered in: Baton Rouge

PREVENTION

Information on open prevention-based clinical trials are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title:Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study)

Purpose: The primary objective of this study is to compare the effect of a supervised weight loss intervention plus health education materials versus health education materials alone upon invasive disease free survival (iDFS) in overweight (BMI 27-29.9 kg/m2) and obese (BMI ≥30kg/m2) women diagnosed with HER-2 negative, stage II and III breast cancer.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick SpellSiva Yadlapati Lauren Zatarain; James CarinderJack Saux, Naveed KhanRobert Fields, Katherine Castle, Maurice King, Charles Wood, Jingya Wang, Jeffery Long, Andrew Elson, R. Scott Bermudez

Offered in: Baton Rouge, Covington, and Houma.

PROSTATE

Information on open prostate trials for breast cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title:  Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Purpose:  This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.

Physicians: Drs. Katherine Castle, Robert Fields, Maurice King, Jingya Wang and Charles Wood; Andrew Elson; Jeffrey Long

Offered in:  Baton Rouge, Covington, Houma

Title: A Phase II, Double – Blinded, Placebo – Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti – Androgen Therapy with Apalutamide in Recurrent Prostate Cancer

Purpose: This phase II trial studies how well radiation therapy with or without Apalutamide works in treating patients with stage III-IV prostate cancer.

Physicians: Drs. Katherine Castle, Jingya Wang, Charles Wood

Offered in: Baton Rouge

RENAL

There are currently no active renal clinical trials. Please check back as we are continuously opening new studies

If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

SKIN

Information on open clinical trials for sarcoma cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title: REtroperitoneal SArcoma Registry (RESAR): Prosepctive Collection of Primary Retroperitoneal Sarcoma Patient’s Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group

Purpose: To prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers.

Physician: Dr. John Lyons

Offered in: Baton Rouge

SKIN

Information on open clinical trials for skin cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form below and a team member will contact you.

Title:  A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

Purpose:  This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery. Ipilimumab and nivolumab may block tumor growth by targeting certain cells. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, and Jack Saux; Robert Gamble, and Naveed Khan.

Offered in:  Baton Rouge, Covington, Houma

Title: A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) For Clinically Detectable Stage III – IV High Risk Melanoma

Purpose: This phase II trial studies how Pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma.

Physicians: Drs. Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Jack Saux; Robert Gamble, Jeanette Kovtun, Daniel LaVie, Genevieve Maronge, Sobia Ozair, Lauren Zatarain and Naveed Khan.

Offered in:  Baton Rouge, Covington, Houma

ABOUT NCORP

Louisiana and Gulf South residents have more options for advanced cancer treatment, thanks to a $5.6 million National Cancer Institute Community Oncology Research Program (NCORP) award. The NCORP grant continues through 2019 and focuses on conducting multi-site cancer clinical trials and cancer care delivery research studies in many Louisiana communities.

The Cancer Center is collaborating with LSU Health Sciences Center-New Orleans and LSU Health Sciences Center-Shreveport, referred to collectively as the Gulf South Minority/Underserved  NCI Community Oncology Research Program (GS-MU-NCORP), to combine our strengths and experiences and bring more state-of-the-art NCI clinical trials to Louisiana cancer patients. Through this effort, we will reach about 80 percent of the state, including the most rural and urban areas where there are often great disparities in cancer care.

This grant expands cancer prevention, screening and survivorship clinical trials to improve early diagnosis and treatment as well as help patients cope with the extended process of getting back to their pre-cancer lives. Additionally, the initiative includes a multidisciplinary approach to patient care to provide the most comprehensive treatment plan for patients.

 

LEARN MORE:

NCORP SITES

Children’s Hospital-Main Campus New Orleans, LA
DeSoto Regional Health System Mansfield, LA
East Jefferson General Metairie, LA
Forrest General Hospital Hattiesburg, MS
Gulfport Memorial Hospital Gulfport, MS
Hattiesburg Clinic Hattiesburg, MS
Highland Clinic Shreveport, LA
Interim LSU Public Hospital New Orleans, LA
LSU Health Baton Rouge, North Clinic, a division of Our Lady of the Lake Baton Rouge, LA
LSU Healthcare Network/Saint Charles New Orleans, LA
Louisiana Hematology Oncology Associates (LHOA) Baton Rouge, LA
Louisiana State University Health Science Center New Orleans, LA
Louisiana State University Health Sciences Center Shreveport Shreveport, LA
Louisiana State University Sciences Center- Monroe Monroe, LA
OLOL – PG Medical Oncology Baton Rouge, LA
Oncology/Hematology Center of the South dba Cancer Care Specialists Houma, LA
Robert Veith MD LLC Metairie, LA
Touro Infirmary New Orleans, LA
Willis-Knighton Medical and Cancer Center Shreveport, LA
Women’s Cancer Care-Covington Covington, LA